500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Receives Complete Response Letter for Vatiquinone NDA
Material Contracts
Financial Results, Reg. FD
Shareholder votes
Provides Corporate Update and Reports First Quarter 2025 Financial Results
PIVOT-HD Study Achieves Primary Endpoint
Annual Report to Security Holders
Investor Presentation
Q2
Q1
FY 2023
Q3
Notice of Exempt Offering of Securities
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Automatic Shelf Registration Statement